Filed on behalf of: Corcept Therapeutics, Inc.

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
TEVA PHARMACEUTICALS USA, INC.,

v.

Petitioner

CORCEPT THERAPEUTICS, INC., Patent Owner

Case PGR2019-00048 U.S. Patent No. 10,195,214

REPLY IN FURTHER SUPPORT OF PATENT OWNER'S MOTION TO EXCLUDE



PGR2019-00048 U.S. Patent No. 10,195,214

TABLE OF CONTENTS

		Page
I.	Teva's Procedural Arguments Lack Merit	1
II.	Teva's Arguments on the Merits Are Baseless	2



TABLE OF AUTHORITIES

<u>Page</u>
Cases
Alexander v. Estepp, 95 F.3d 312 (4th Cir. 1996)
Chicago Mercantile Exchange, Inc. v. 5 th Market, Inc., CBM2014-00114, Paper 35 (P.T.A.B. Aug. 18, 2015)1-2
Dalgic v. Misericordia Univ., No. 3:16-cv-0443, 2019 WL 2867236 (M.D. Pa. July 3, 2019)4
Johns Manville Corp. v. Knauf Insulation, Inc., IPR2016-00130, Paper 35 (P.T.A.B. May 8, 2017)
Seaberry N. Am. Inc. v. Lincoln Global, Inc., IPR2016-00840, Paper 60 (P.T.A.B. Oct. 2, 2017)5
Smith v. Isuzu Motors Ltd., 137 F.3d 859 (5th Cir. 1998)
Rules and Regulations
Fed. R. Evid. 803(8)
Fed. R. Evid. 901
Other
Fed. R. Evid. 803 Advisory Committee's Notes
Motion to Exclude, <i>Eli Lilly & Co. v. Teva Pharm. Int'l</i> , IPR2018-01710, Paper 51 (P.T.A.B. Dec. 11, 2019)



I. Teva's Procedural Arguments Lack Merit

Teva preliminarily asserts that Corcept's motion should be denied on two procedural grounds. *First*, Teva contends that "Corcept's motion does not contest the *admissibility* of the thesis ... and should be denied for that reason alone."

Paper 45 at 1. This is demonstrably false. The Motion to Exclude contests the admissibility of the thesis in no uncertain terms. *See* Paper 44 at 1 ("Exhibit 1075 should be excluded pursuant to FRE 901"); *see also id.* at 5.

Second, Teva contends that "arguments as to the public accessibility of [Ex. 1075] should have been presented in [the] Patent Owner Sur-Reply." Paper 45 at 3. Not so. The Board has considered public accessibility under FRE 901 where, as here, "authentication and hearsay issues as they relate to the printed date information on [the alleged prior art] are ... intertwined with admissibility." Johns Manville Corp. v. Knauf Insulation, Inc., IPR2016-00130, Paper 35 at 17 (P.T.A.B. May 8, 2017). The Chicago Mercantile case that Teva cites stands for the same proposition—there, the Board explained that "addressing the admissibility of evidence, e.g., authenticity or hearsay, underlying the factual determinations of whether [the reference] is a prior art printed publication may be the subject of a motion to exclude." CBM2014-00114, Paper 35 at 52.

These are the same grounds on which Corcept moved to exclude Ex. 1075.

Corcept expressly argued that Teva "put forth insufficient evidence indicating that



Exhibit 1075 was cataloged in any library," because the only "evidence" Teva offered in support of its alleged availability is an email chain that the Board should refuse to consider on hearsay grounds. Paper 44 at 3-4. In other words, Corcept's motion properly addresses the admissibility of the evidence "underlying the factual determinations of whether [Ex. 1075] is a prior art printed publication." *Chicago Mercantile*, CBM2014-00114, Paper 35 at 52. Accordingly, Corcept's motion is procedurally proper under the Board's precedent.

Moreover, Teva and its lead counsel agreed with and embraced this approach less than one year ago in moving to exclude a thesis "under FRE 901 because [its proponent] ... ha[d] not provided sufficient information regarding its authenticity as a publicly accessible document." Motion to Exclude, *Eli Lilly & Co. v. Teva Pharm. Int'l.*, IPR2018-01710, Paper 51 at 2 (P.T.A.B. Dec. 11, 2019). Teva and its counsel advocated to the Board that "[t]he *public accessibility* of [a thesis] is *an essential part of the foundation analysis*." *Id.* (emphasis added).

Thus, Teva's opposition on procedural grounds should be rejected.

II. Teva's Arguments on the Merits Are Baseless

Teva's response on the merits fares no better. Teva argues that Ex. 1075 was publicly available because "the thesis has been indexed in the Central Catalogue of Dutch libraries for the past 28 years *and* has been available online since 2013." Paper 45 at 4. The only "evidence" that Teva cites in support of its



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

